B
Bernard Desablens
Researcher at South University
Publications - 64
Citations - 4294
Bernard Desablens is an academic researcher from South University. The author has contributed to research in topics: Chemotherapy & Survival rate. The author has an hindex of 28, co-authored 64 publications receiving 4158 citations.
Papers
More filters
Journal ArticleDOI
A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic Leukemia
Pierre Fenaux,Claude Chastang,Sylvie Chevret,Miguel A. Sanz,Hervé Dombret,Eric Archimbaud,Martin F. Fey,Consuelo Rayon,Françoise Huguet,Jean-Jacques Sotto,Claude Gardin,Pascale Cony Makhoul,Philippe Travade,Eric Solary,Nathalie Fegueux,Dominique Bordessoule,Jesús F. San Miguel,Harmut Link,Bernard Desablens,Aspasia Stamatoullas,E. Deconinck,Frédéric Maloisel,Sylvie Castaigne,Claude Preudhomme,Laurent Degos +24 more
TL;DR: It is strongly suggest that early addition of chemotherapy to ATRA and maintenance therapy combining continuous CT and intermittent ATRA can reduce the incidence of relapse in APL.
Journal ArticleDOI
Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients.
Michel Leporrier,Sylvie Chevret,Bruno Cazin,Najda Boudjerra,Pierre Feugier,Bernard Desablens,M. J. Rapp,Jérôme Jaubert,Claudie Autrand,Marine Divine,Brigitte Dreyfus,Karim Maloum,Philippe Travade,Guillaume Dighiero,Jacques-Louis Binet,Claude Chastang +15 more
TL;DR: For patients with stage B and C CLL first-line fludarabine and ChOP regimens both provided similar overall survival and close response rates, and better results than CAP, but there was an increase in clinical remission rate and a trend toward a better tolerance of fludARabine over ChOP that may influence the choice between these regimens as front-line treatments in patients with CLL.
Journal ArticleDOI
Comparison of Autologous Bone Marrow Transplantation and Intensive Chemotherapy as Postremission Therapy in Adult Acute Myeloid Leukemia
Jean-Luc Harousseau,Jean-Yves Cahn,Bernard Pignon,Francis Witz,Noel Milpied,Martine Delain,Bruno Lioure,Thierry Lamy,Bernard Desablens,François Guilhot,Denis Caillot,JF Abgrall,Sylvie François,Jean Briere,Denis Guyotat,Philippe Casassus,Bruno Audhuy,Zéra Tellier,Patrick Hurteloup,Patrick Hervé +19 more
TL;DR: Three intensive consolidation strategies are currently proposed to younger adults with acute myeloid leukemia (AML) in first complete remission (CR): allogeneic or autologous bone marrow transplantation (BMT) and intensive consolidation chemotherapy (ICC).
Journal ArticleDOI
Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly.
Hervé Tilly,Sylvie Castaigne,Dominique Bordessoule,Philippe Casassus,P.Y. Le Prise,G Tertian,Bernard Desablens,Michel Henry-Amar,Laurent Degos +8 more
TL;DR: In a selected group of elderly patients with de novo ANLL a higher number of CRs may be obtained with intensive chemotherapy, but that with LD ARA-C, the number of early deaths is lower, and long-lasting PRs are obtained, resulting in a similar overall survival.
Journal ArticleDOI
High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS
Eric Deconinck,Charles Foussard,Noel Milpied,Philippe Bertrand,Patrick Michenet,Pascale Cornillet-Lefebvre,Martine Escoffre-Barbe,Hervé Maisonneuve,Vincent Delwail,Remy Gressin,Eric Legouffe,Jean-Pierre Vilque,Bernard Desablens,Jérôme Jaubert,Jean-François Ramée,Arash Jenabian,Antoine Thyss,Annick Le Pourhiet-Le Mevel,Philippe Travade,Roselyne Delepine,Philippe Colombat +20 more
TL;DR: Patients treated with high-dose immunochemotherapy followed by purged autologous stem-cell transplantation had a higher response rate and a longer median event-free survival, but this did not translate into a better survival rate due to an excess of secondary malignancies after transplantation.